Stay updated with breaking news from 52887210. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Lexicon Pharmaceuticals (NASDAQ:LXRX – Get Free Report)‘s stock had its “outperform” rating reaffirmed by research analysts at Leerink Partnrs in a note issued to investors on Tuesday, Zacks.com reports. Leerink Partnrs also issued estimates for Lexicon Pharmaceuticals’ Q1 2024 earnings at ($0.13) EPS, Q2 2024 earnings at ($0.13) EPS, Q3 2024 earnings at ($0.13) EPS, […]
Lexicon Pharmaceuticals (NASDAQ:LXRX – Get Free Report)‘s stock had its “outperform” rating reissued by research analysts at Leerink Partnrs in a note issued to investors on Tuesday, Zacks.com reports. Leerink Partnrs also issued estimates for Lexicon Pharmaceuticals’ Q1 2024 earnings at ($0.13) EPS, Q2 2024 earnings at ($0.13) EPS, Q3 2024 earnings at ($0.13) EPS, […]
Lexicon Pharmaceuticals (NASDAQ:LXRX – Get Free Report)‘s stock had its “outperform” rating reaffirmed by investment analysts at Leerink Partnrs in a report issued on Tuesday, Zacks.com reports. Leerink Partnrs also issued estimates for Lexicon Pharmaceuticals’ Q1 2024 earnings at ($0.13) EPS, Q2 2024 earnings at ($0.13) EPS, Q3 2024 earnings at ($0.13) EPS, Q4 2024 […]
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX – Free Report) – Research analysts at Leerink Partnrs issued their Q1 2024 earnings per share estimates for shares of Lexicon Pharmaceuticals in a research report issued on Tuesday, April 30th. Leerink Partnrs analyst R. Ruiz anticipates that the biopharmaceutical company will post earnings per share of ($0.13) for the quarter. […]
Lexicon Pharmaceuticals (NASDAQ:LXRX – Get Free Report)‘s stock had its “outperform” rating reissued by equities research analysts at Leerink Partnrs in a report released on Tuesday, Zacks.com reports. Leerink Partnrs also issued estimates for Lexicon Pharmaceuticals’ Q1 2024 earnings at ($0.13) EPS, Q2 2024 earnings at ($0.13) EPS, Q3 2024 earnings at ($0.13) EPS, Q4 […]